Abstract

Ca²⁺ is a ubiquitous cellular signal. Altered expression of specific Ca²⁺ channels and pumps are characterizing features of some cancers. The ability of Ca²⁺ to regulate both cell death and proliferation, combined with the potential for pharmacological modulation, offers the opportunity for a set of new drug targets in cancer. However, the ubiquity of the Ca²⁺ signal is often mistakenly presumed to thwart the specific therapeutic targeting of proteins that transport Ca²⁺. This Review presents evidence to the contrary and addresses the question: which Ca²⁺ channels and pumps should be targeted?

Author affiliations

1. School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia, 4072.

Correspondence to: Gregory R. Monteith¹ Email: greg@pharmacy.uq.edu.au

Correspondence to: Sarah J. Roberts-Thomson¹ Email: sarah@pharmacy.uq.edu.au

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.